Literature DB >> 31262190

LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.

Qing Ge1, Li Zhao1, Xiao-Min Ren1, Peng Ye1, Zuo-Ying Hu1.   

Abstract

Entities:  

Keywords:  LCZ696; NF-κB; apoptosis; diabetic cardiomyopathy; inflammation; oxidative stress

Mesh：

Substances：

Year:  2019        PMID： 31262190      PMCID： PMC6879777          DOI： 10.1177/1535370219861283

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


× No keyword cloud information.
  24 in total

1.  Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death.

Authors:  Partha Mukhopadhyay; Mohanraj Rajesh; Béla Horváth; Sándor Bátkai; Ogyi Park; Galin Tanchian; Rachel Y Gao; Vivek Patel; David A Wink; Lucas Liaudet; György Haskó; Raphael Mechoulam; Pál Pacher
Journal:  Free Radic Biol Med       Date:  2011-03-11       Impact factor: 7.376

2.  Inhibition of JNK and p38 MAPK-mediated inflammation and apoptosis by ivabradine improves cardiac function in streptozotocin-induced diabetic cardiomyopathy.

Authors:  Guangfeng Zuo; Xiaomin Ren; Xuesong Qian; Peng Ye; Jie Luo; Xiaofei Gao; Junjie Zhang; Shaoliang Chen
Journal:  J Cell Physiol       Date:  2018-08-01       Impact factor: 6.384

Review 3.  Oxidative stress: a key contributor to diabetic cardiomyopathy.

Authors:  Madhu Khullar; Abd Al-Rahman S Al-Shudiefat; Ana Ludke; Gursonika Binepal; Pawan K Singal
Journal:  Can J Physiol Pharmacol       Date:  2010-03       Impact factor: 2.273

4.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors:  Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

5.  c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling.

Authors:  Qiangrong Liang; Orlando F Bueno; Benjamin J Wilkins; Chia-Yi Kuan; Ying Xia; Jeffery D Molkentin
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

6.  LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.

Authors:  Yasunori Suematsu; Shin-Ichiro Miura; Masaki Goto; Yoshino Matsuo; Tadaaki Arimura; Takashi Kuwano; Satoshi Imaizumi; Atsushi Iwata; Eiji Yahiro; Keijiro Saku
Journal:  Eur J Heart Fail       Date:  2016-01-07       Impact factor: 15.534

7.  Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion.

Authors:  Hang Yin; Lee Chao; Julie Chao
Journal:  Life Sci       Date:  2007-11-09       Impact factor: 5.037

8.  Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy.

Authors:  Vajir Malek; Anil Bhanudas Gaikwad
Journal:  Cardiovasc Res       Date:  2019-02-01       Impact factor: 10.787

Review 9.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.

Authors:  Goodarz Danaei; Mariel M Finucane; Yuan Lu; Gitanjali M Singh; Melanie J Cowan; Christopher J Paciorek; John K Lin; Farshad Farzadfar; Young-Ho Khang; Gretchen A Stevens; Mayuree Rao; Mohammed K Ali; Leanne M Riley; Carolyn A Robinson; Majid Ezzati
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

10.  Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design.

Authors:  Dany Jaffuel; Nicolas Molinari; Philippe Berdague; Atul Pathak; Michel Galinier; Marion Dupuis; Jean-Etienne Ricci; Jean-Pierre Mallet; Arnaud Bourdin; François Roubille
Journal:  ESC Heart Fail       Date:  2018-02-22
View more
  16 in total

Review 1.  Basic Mechanisms of Diabetic Heart Disease.

Authors:  Rebecca H Ritchie; E Dale Abel
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

2.  [Dihydromyricetin improves cardiac insufficiency by inhibiting HMGB1 in diabetic rats].

Authors:  S Liu; Q Liu; Q Peng; Y Zhang; J Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

3.  LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice.

Authors:  Qing Ge; Li Zhao; Chen Liu; Xiaoming Ren; Yi-Hui Yu; Chang Pan; Zuoying Hu
Journal:  Biomed Res Int       Date:  2020-01-11       Impact factor: 3.411

Review 4.  Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy.

Authors:  Jinjing Wei; Yongting Zhao; Haihai Liang; Weijie Du; Lihong Wang
Journal:  Acta Pharm Sin B       Date:  2021-08-28       Impact factor: 11.413

5.  SFRP2 Improves Mitochondrial Dynamics and Mitochondrial Biogenesis, Oxidative Stress, and Apoptosis in Diabetic Cardiomyopathy.

Authors:  Tianyi Ma; Xiaohui Huang; Haoxiao Zheng; Guolin Huang; Weiwen Li; Xinyue Liu; Jingjing Liang; Yue Cao; Yunzhao Hu; Yuli Huang
Journal:  Oxid Med Cell Longev       Date:  2021-11-08       Impact factor: 6.543

6.  Whole Exome Sequencing Study in a Family with Type 2 Diabetes Mellitus.

Authors:  Xiaowei Zhou; Weichang Guo; Hejia Yin; Jie Chen; Liju Ma; Qiuping Yang; Yan Zhao; Shaoyou Li; Weijun Liu; Huifang Li
Journal:  Int J Gen Med       Date:  2021-11-16

7.  Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy via Inhibition of TGF-β/Smad Pathway.

Authors:  George J Dugbartey; Quinsker L Wonje; Karl K Alornyo; Louis Robertson; Ismaila Adams; Vincent Boima; Samuel D Mensah
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

8.  Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction.

Authors:  Kanokwan Bunsawat; Stephen M Ratchford; Jeremy K Alpenglow; Soung Hun Park; Catherine L Jarrett; Josef Stehlik; Adam S Smith; Russell S Richardson; D Walter Wray
Journal:  J Appl Physiol (1985)       Date:  2020-11-19

9.  Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study.

Authors:  Kanokwan Bunsawat; Stephen M Ratchford; Jeremy K Alpenglow; Josef Stehlik; Adam S Smith; Russell S Richardson; D Walter Wray
Journal:  Auton Neurosci       Date:  2021-06-24       Impact factor: 2.355

10.  LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats.

Authors:  Toru Miyoshi; Kazufumi Nakamura; Naofumi Amioka; Omer F Hatipoglu; Tomoko Yonezawa; Yukihiro Saito; Masashi Yoshida; Satoshi Akagi; Hiroshi Ito
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.